WO2016129061A1 - 生体物質定量方法、病理診断支援システム及びプログラム - Google Patents
生体物質定量方法、病理診断支援システム及びプログラム Download PDFInfo
- Publication number
- WO2016129061A1 WO2016129061A1 PCT/JP2015/053679 JP2015053679W WO2016129061A1 WO 2016129061 A1 WO2016129061 A1 WO 2016129061A1 JP 2015053679 W JP2015053679 W JP 2015053679W WO 2016129061 A1 WO2016129061 A1 WO 2016129061A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fluorescent
- specimen
- biological material
- standard
- fluorescence
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6428—Measuring fluorescence of fluorescent products of reactions or of fluorochrome labelled reactive substances, e.g. measuring quenching effects, using measuring "optrodes"
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
- G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
- G01N21/64—Fluorescence; Phosphorescence
- G01N21/6486—Measuring fluorescence of biological material, e.g. DNA, RNA, cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/84—Systems specially adapted for particular applications
- G01N21/88—Investigating the presence of flaws or contamination
- G01N21/93—Detection standards; Calibrating baseline adjustment, drift correction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/0002—Inspection of images, e.g. flaw detection
- G06T7/0012—Biomedical image inspection
- G06T7/0014—Biomedical image inspection using an image reference approach
- G06T7/0016—Biomedical image inspection using an image reference approach involving temporal comparison
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T7/00—Image analysis
- G06T7/90—Determination of colour characteristics
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10024—Color image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10056—Microscopic image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/10—Image acquisition modality
- G06T2207/10064—Fluorescence image
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30004—Biomedical image processing
- G06T2207/30024—Cell structures in vitro; Tissue sections in vitro
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06T—IMAGE DATA PROCESSING OR GENERATION, IN GENERAL
- G06T2207/00—Indexing scheme for image analysis or image enhancement
- G06T2207/30—Subject of image; Context of image processing
- G06T2207/30242—Counting objects in image
Definitions
- the present invention relates to a biological substance quantification method, a pathological diagnosis support system, and a program using luminance information of a fluorescent substance.
- an average luminance value per phosphor particle is calculated by analyzing a luminance distribution peak of a fluorescent emission luminescent spot from a tissue specimen stained with a phosphor that can bind to a biological substance.
- a method has been proposed in which the number of bright spots in a tissue specimen is measured to increase the quantitative accuracy of the expression level of a biological substance.
- pathological diagnosis for example, comparison of diagnostic results before and after treatment in the same patient, for example, not only specimens that have simultaneously quantified biological substances, but also quantitative results between various specimens with different operators, measurement systems, and staining conditions It is desirable to be able to compare and evaluate.
- a main object of the present invention is to provide a biological material quantification method and program capable of accurately quantifying the amount of a specific biological material in a specimen by correcting quantification errors caused by differences in operators and measurement systems. It is in.
- the invention of the biological material quantification method comprises: In the biological material quantification method for quantifying the expression level of the biological material in a specimen stained with a staining reagent capable of staining a specific biological material using a fluorescent material, A fluorescence image input step of inputting a fluorescence image representing the expression of the biological material in the specimen as a fluorescence bright spot; A fluorescence quantification step of calculating an evaluation value obtained by quantitatively evaluating the fluorescent luminescent spot from the fluorescence image; In a standard specimen in which the expression level of the biological material is measured in advance, a standard fluorescent image representing the expression of the biological substance based on staining under the same conditions as the staining of the specimen is represented by the same conditions as in the fluorescence image input step Standard fluorescence image input process to be input in A standard fluorescence quantification step of calculating an evaluation value obtained by quantitatively evaluating the fluorescent luminescent spot from the standard fluorescence image under the same conditions as the fluorescence quant
- the invention according to claim 2 is the biological material quantification method according to claim 1,
- the correlation calculation step create a calibration curve indicating the evaluation value of the fluorescence bright spot of the standard fluorescence image with respect to the expression level of the biological material in the standard specimen
- the conversion step the evaluation value of the fluorescent luminescent spot of the fluorescent image is converted into the expression level of the biological material in the specimen based on the calibration curve.
- the invention according to claim 3 is the biological material quantification method according to claim 1 or 2
- the standard specimen is a cultured cell cultured on a base material.
- the invention according to claim 4 is the biological material quantification method according to any one of claims 1 to 3,
- the biological material is a protein.
- the invention according to claim 5 is the biological material quantification method according to any one of claims 1 to 4,
- the staining reagent includes fluorescent particles in which a plurality of the fluorescent substances are integrated.
- a pathological diagnosis support system for quantifying the expression level of the biological material in a specimen stained with a staining reagent capable of staining a specific biological material using a fluorescent material A fluorescence image input means for inputting a fluorescence image representing the expression of the biological material in the specimen as a fluorescence bright spot; Fluorescence quantification means for calculating an evaluation value obtained by quantitatively evaluating the fluorescent luminescent spot from the fluorescence image;
- a standard fluorescence image representing the expression of the biological substance based on staining under the same conditions as the staining of the specimen is expressed by the same condition as the fluorescence image input means
- the invention of the program according to claim 7 is: A computer for quantifying the expression level of the biological material in a specimen stained with a staining reagent capable of staining a specific biological material using a fluorescent material; Fluorescence image input means for inputting a fluorescence image representing the expression of the biological material in the specimen as a fluorescent luminescent spot, Fluorescence quantification means for calculating an evaluation value obtained by quantitatively evaluating the fluorescent luminescent spot from the fluorescence image, In a standard specimen in which the expression level of the biological material is measured in advance, a standard fluorescence image representing the expression of the biological substance based on staining under the same conditions as the staining of the specimen is expressed by the same condition as the fluorescence image input means Standard fluorescence image input means to input with, A standard fluorescence quantification means for calculating an evaluation value obtained by quantitatively evaluating the fluorescent luminescent spot from the standard fluorescence image under the same conditions as the fluorescence quantification means, Correlation calculating means for calculating the correlation between the expression
- the amount of a specific biological substance in a specimen can be accurately quantified.
- FIG. 5 S4 It is a figure which shows an example of a bright field image. It is a figure which shows the image (cell image) from which the cell area
- FIG. 1 shows an example of the overall configuration of a pathological diagnosis support system 100 using the biological material quantification method of the present invention.
- the pathological diagnosis support system 100 includes a specimen to be observed (hereinafter referred to as “target specimen”) stained with a predetermined staining reagent, and a specimen (hereinafter referred to as “standard specimen”) in which a specific biological substance concentration is quantified in advance. And a feature amount that quantitatively expresses the expression of a specific biological substance in the target specimen by analyzing the acquired microscope image.
- the pathological diagnosis support system 100 is configured by connecting a microscope image acquisition apparatus 1A and an image processing apparatus 2A so as to be able to transmit and receive data via an interface such as a cable 3A.
- the connection method between the microscope image acquisition device 1A and the image processing device 2A is not particularly limited.
- the microscope image acquisition device 1A and the image processing device 2A may be connected via a LAN (Local Area Network) or may be configured to be connected wirelessly.
- LAN Local Area Network
- the microscope image acquisition apparatus 1A is a known optical microscope with a camera, and acquires a microscope image of a specimen on a slide placed on a slide fixing stage and transmits it to the image processing apparatus 2A.
- the microscope image acquisition apparatus 1A includes an irradiation unit, an imaging unit, an imaging unit, a communication I / F, and the like.
- the irradiation means is composed of a light source, a filter, and the like, and irradiates the specimen on the slide placed on the slide fixing stage with light.
- the imaging means is composed of an eyepiece lens, an objective lens, and the like, and images transmitted light, reflected light, or fluorescence emitted from the specimen on the slide by the irradiated light.
- the imaging means is a microscope-installed camera that includes a CCD (Charge Coupled Device) sensor and the like, captures an image formed on the imaging surface by the imaging means, and generates digital image data of the microscope image.
- the communication I / F transmits image data of the generated microscope image to the image processing apparatus 2A.
- the microscope image acquisition apparatus 1A includes a bright field unit that combines an irradiation unit and an imaging unit suitable for bright field observation, and a fluorescence unit that combines an irradiation unit and an imaging unit suitable for fluorescence observation. It is possible to switch between bright field / fluorescence by switching units.
- the microscope image acquisition device 1A is not limited to a microscope with a camera.
- a virtual microscope slide creation device for example, a special table that acquires a microscope image of the entire specimen by scanning a slide on a microscope slide fixing stage. 2002-514319
- the virtual microscope slide creation device it is possible to acquire image data that allows the entire specimen image on the slide to be viewed at once on the display unit.
- the image processing apparatus 2A calculates the expression distribution of a specific biological material in the target specimen by analyzing the microscope image transmitted from the microscope image acquisition apparatus 1A.
- FIG. 2 shows a functional configuration example of the image processing apparatus 2A.
- the image processing apparatus 2 ⁇ / b> A includes a control unit 21, an operation unit 22, a display unit 23, a communication I / F 24, a storage unit 25, and the like, and each unit is connected via a bus 26. Yes.
- the control unit 21 includes a CPU (Central Processing Unit), a RAM (Random Access Memory), and the like.
- the control unit 21 executes various processes in cooperation with various programs stored in the storage unit 25, and performs image processing 2A. Overall control of the operation.
- the control unit 21 executes image processing (see steps S4 to S6 in FIG. 5) in cooperation with a program stored in the storage unit 25, and performs a fluorescence determination process, a standard fluorescence determination process, and a correlation calculation process. And a function as means for executing the conversion step.
- the operation unit 22 includes a keyboard having character input keys, numeric input keys, various function keys, and the like, and a pointing device such as a mouse, and a key pressing signal pressed by the keyboard and an operation signal by the mouse. Are output to the control unit 21 as an input signal.
- the display unit 23 includes, for example, a monitor such as a CRT (Cathode Ray Tube) or an LCD (Liquid Crystal Display), and displays various screens in accordance with display signal instructions input from the control unit 21.
- a monitor such as a CRT (Cathode Ray Tube) or an LCD (Liquid Crystal Display)
- LCD Liquid Crystal Display
- the communication I / F 24 is an interface for transmitting and receiving data to and from external devices such as the microscope image acquisition device 1A.
- the communication I / F 24 functions as means for executing a standard fluorescence image input process and a fluorescence image input process.
- the storage unit 25 includes, for example, an HDD (Hard Disk Drive), a semiconductor nonvolatile memory, or the like. As described above, the storage unit 25 stores various programs, various data, and the like.
- the image processing apparatus 2A may include a LAN adapter, a router, and the like and be connected to an external device via a communication network such as a LAN.
- the image processing apparatus 2A in the present embodiment preferably performs analysis using the bright field image and the fluorescence image transmitted from the microscope image acquisition apparatus 1A.
- the bright field image is a microscopic image obtained by enlarging and photographing a specimen stained with H (hematoxylin) staining reagent and HE (hematoxylin-eosin) staining reagent in a bright field in the microscope image acquisition apparatus 1A. And it is a cell form image showing the form of the cell in the said specimen.
- Hematoxylin is a blue-violet pigment that stains cell nuclei, bone tissue, part of cartilage tissue, serous components, etc. (basophilic tissue, etc.).
- Eosin is a red to pink pigment that stains the cytoplasm, connective tissue of soft tissues, red blood cells, fibrin, endocrine granules, etc. (eosinophilic tissues, etc.).
- FIG. 3 shows an example of a bright field image obtained by photographing a specimen that has been subjected to HE staining.
- a fluorescent image is obtained by using a microscope image acquisition apparatus 1A for a specimen stained with a staining reagent containing a fluorescent substance bound with a biological substance recognition site that specifically binds and / or reacts with a specific biological substance. It is a microscope image obtained by irradiating excitation light of a wavelength to emit a fluorescent material (fluorescence) and enlarging and photographing this fluorescence. That is, the fluorescence that appears in the fluorescence image indicates the expression of a specific biological material corresponding to the biological material recognition site in the specimen.
- FIG. 4 shows an example of the fluorescence image.
- fluorescent substance examples include fluorescent organic dyes and quantum dots (semiconductor particles). When excited by ultraviolet to near infrared light having a wavelength in the range of 200 to 700 nm, it preferably emits visible to near infrared light having a wavelength in the range of 400 to 1100 nm.
- fluorescent organic dyes fluorescein dye molecules, rhodamine dye molecules, Alexa Fluor (registered trademark, manufactured by Invitrogen) dye molecules, BODIPY (registered trademark, manufactured by Invitrogen) dye molecules, cascade dye molecules, coumarin dyes Examples thereof include dye molecules, eosin dye molecules, NBD dye molecules, pyrene dye molecules, Texas Red dye molecules, and cyanine dye molecules.
- quantum dots containing II-VI group compounds, III-V group compounds, or group IV elements as components ("II-VI group quantum dots”, "III-V group quantum dots”, " Or “Group IV quantum dots”). You may use individually or what mixed multiple types.
- CdSe CdS, CdS, CdTe, ZnSe, ZnS, ZnTe, InP, InN, InAs, InGaP, GaP, GaAs, Si, and Ge, but are not limited thereto.
- a fluorescent substance-containing nanoparticle in which a plurality of fluorescent substances are integrated can be used as a fluorescent substance used as a staining reagent for obtaining a fluorescent image.
- the fluorescent particles are those in which a fluorescent substance is dispersed inside the nanoparticles, and the fluorescent substance and the nanoparticles themselves may or may not be chemically bonded.
- the material constituting the nanoparticles is not particularly limited, and examples thereof include polystyrene, polylactic acid, silica, and melamine.
- the quantum dot which used the quantum dot as the core and provided the shell on it can also be used as a fluorescent particle.
- CdSe / ZnS when the core is CdSe and the shell is ZnS, it is expressed as CdSe / ZnS.
- CdSe / ZnS, CdS / ZnS, InP / ZnS, InGaP / ZnS, Si / SiO 2 , Si / ZnS, Ge / GeO 2 , Ge / ZnS, and the like can be used, but are not limited thereto.
- quantum dots those subjected to surface treatment with an organic polymer or the like may be used as necessary.
- examples thereof include CdSe / ZnS having a surface carboxy group (manufactured by Invitrogen), CdSe / ZnS having a surface amino group (manufactured by Invitrogen), and the like.
- the fluorescent particles used in the present embodiment can be produced by a known method.
- the particles of the fluorescent dye are combined with the raw material monomer to synthesize the particles. Any method may be used, such as a method of introducing a fluorescent dye onto a resin and introducing it.
- polystyrene nanoparticles encapsulating a fluorescent organic dye are described in a copolymerization method using an organic dye having a polymerizable functional group described in US Pat. No. 4,326,008 (1982) or in US Pat. No. 5,326,692 (1992). It can be produced by using an impregnation method of fluorescent organic dye into polystyrene nanoparticles.
- polymer nanoparticles encapsulating quantum dots can be produced by using the method of impregnating quantum nanoparticles into polystyrene nanoparticles described in Nature Biotechnology, Vol. 19, page 631 (2001).
- the average particle diameter of the fluorescent particles used in the present embodiment is not particularly limited, but those having a large particle diameter are difficult to accurately measure because the luminance is easily saturated when a plurality of particles are close to each other. Smaller diameters have a lower integrated luminance value and the fluorescent particle signal is buried in the background noise (camera noise and cell autofluorescence).
- the average particle size is preferably 40 to 280 nm.
- the average particle diameter is obtained by measuring the cross-sectional area of a particle from an electron micrograph taken using a scanning electron microscope (SEM) and taking the diameter of the circle when each measured value is the area of the circle as the particle diameter. In the present application, the particle size of 1000 particles was measured, and the arithmetic average was taken as the average particle size.
- the biological material recognition site is a site that specifically binds and / or reacts with the target biological material.
- the target biological substance is not particularly limited as long as a substance that specifically binds to the target biological substance exists, but typically, protein (peptide), nucleic acid (oligonucleotide, polynucleotide), antibody, etc. Is mentioned. Accordingly, substances that bind to the target biological substance include antibodies that recognize the protein as an antigen, other proteins that specifically bind to the protein, and nucleic acids having a base sequence that hybridizes to the nucleic acid. Is mentioned.
- an anti-HER2 antibody that specifically binds to HER2 that is a protein expressed on the cell surface a Ki67 antibody that specifically binds to Ki67 protein that is a marker of cell proliferation expressed in the cell nucleus, and an estrogen that is expressed in the cell nucleus
- examples thereof include an anti-ER antibody that specifically binds to a receptor (ER), an anti-actin antibody that specifically binds to actin that forms a cytoskeleton, and the like.
- anti-HER2 antibody, anti-ER antibody, or anti-Ki67 antibody bound to fluorescent particles can be used for breast cancer medication selection and is preferred.
- antigens examples include M. actin, MS actin, SM actin, ACTH, Alk-1, ⁇ 1-antichymotrypsin, ⁇ 1-antitrypsin, AFP, bcl-2, bcl-6, ⁇ -catenin, BCA 225, CA19-9, CA125 , Calcitonin, calretinin, CD1a, CD3, CD4, CD5, CD8, CD10, CD15, CD20, CD21, CD23, CD30, CD31, CD34, CD43, CD45, CD45R, CD56, CD57, CD61, CD68, CD79a, "CD99, MIC2 ", CD138, chromogranin, c-KIT, c-MET, collagen type IV, Cox-2, cyclin D1, keratin, cytokeratin (high molecular weight), pankeratin, pankeratin
- examples of the specific nucleic acid gene that has been pointed out to be associated with a disease can include the following, and probes that recognize each specific nucleic acid gene are available as BAC probes: Can be created based on general knowledge. Specific examples of specific nucleic acid genes are as follows. HER2, TOP2A, HER3, EGFR, P53, MET, etc. are mentioned as genes related to cancer growth and molecular target drug response. Furthermore, the following genes are known as various cancer-related genes. Can be mentioned.
- Tyrosine kinase-related genes include ALK, FLT3, AXL, FLT4 (VEGFR3, DDR1, FMS (CSF1R), DDR2, EGFR (ERBB1), HER4 (ERBB4), EML4-ALK, IGF1R, EPHA1, INSR, EPHA2, IRR (INSRR) ), EPHA3, KIT, EPHA4, LTK, EPHA5, MER (MERTK), EPHA6, MET, EPHA7, MUSK, EPHA8, NPM1-ALK, EPHB1, PDGFR ⁇ (PDGFRA), EPHB2, PDGFR ⁇ (PDGFRB), EPHEP3, T RON (MST1R), FGFR1, ROS (ROS1), FGFR2, TIE2 (TEK), FGFR3, TRKA (NTRK1), FGFR4, TRKB (NT RK2), FLT1 (VEGFR1), TRKC (NTRK3), and breast cancer-related genes are ATM, BRCA1, BRCA2, BRCA3, CC
- Cancer-related genes include APC, MSH6, AXIN2, MYH, BMPR1A, p53, DCC, PMS2, KRAS2 (or Ki-ras), PTEN, MLH1, and SMA.
- MSH2, STK11, MSH6 Lung cancer-related genes include ALK, PTEN, CCND1, RASSF1A, CDKN2A, RB1, EGFR, RET, EML4, ROS1, KRAS2, TP53, MYC.
- genes include Axin1, MALAT1, b-catenin, p16 INK4A, c-ERBB-2, p53, CTNNB1, RB1, Cyclin D1, SMAD2, EGFR, SMAD4, IGFR2, TCF1, and KRAS.
- Related genes include Alpha, PRCC, ASPSCR1, PSF, CLTC, TFE3, p54nrb / NONO, and TFEB As thyroid cancer-related genes, AKAP10, NTRK1, and AKA 9, RET, BRAF, TFG, ELE1, TPM3, H4 / D10S170, TPR and the like.
- Examples of ovarian cancer-related genes include AKT2, MDM2, BCL2, MYC, BRCA1, NCOA4, CDKN2A, p53, ERBB2, PIK3CA, GATA4, RB, HRAS, RET, KRAS, and RNASET2.
- Examples of prostate cancer-related genes include AR, KLK3, BRCA2, MYC, CDKN1B, NKX3.1, EZH2, p53, GSTP1, and PTEN.
- Examples of bone tumor-related genes include CDH11, COL12A1, CNBP, OMD, COL1A1, THRAP3, COL4A5, and USP6.
- the mode of binding between the biological substance recognition site and the fluorescent particles is not particularly limited, and examples thereof include covalent bonding, ionic bonding, hydrogen bonding, coordination bonding, physical adsorption, and chemical adsorption.
- a bond having a strong bonding force such as a covalent bond is preferred from the viewpoint of bond stability.
- an organic molecule that connects between the biological substance recognition site and the fluorescent particle.
- a polyethylene glycol chain can be used, and SM (PEG) 12 manufactured by Thermo Scientific can be used.
- a silane coupling agent that is a compound widely used for bonding an inorganic substance and an organic substance can be used.
- This silane coupling agent is a compound having an alkoxysilyl group that gives a silanol group by hydrolysis at one end of the molecule and a functional group such as a carboxyl group, an amino group, an epoxy group, an aldehyde group at the other end, Bonding with an inorganic substance through an oxygen atom of the silanol group.
- silane coupling agent having a polyethylene glycol chain (for example, PEG-silane no. SIM6492.7 manufactured by Gelest), etc. Is mentioned.
- silane coupling agent you may use 2 or more types together.
- the obtained fluorescent organic dye-containing nanoparticles are dispersed in pure water, aminopropyltriethoxysilane is added, and the mixture is reacted at room temperature for 12 hours.
- fluorescent organic dye-containing nanoparticles whose surface is modified with an aminopropyl group can be obtained by centrifugation or filtration.
- the antibody by reacting an amino group with a carboxyl group in the antibody, the antibody can be bound to the fluorescent organic dye-containing nanoparticles via an amide bond.
- a condensing agent such as EDC (1-Ethyl-3- [3-Dimethylaminopropyl] carbodiimide Hydrochloride: Pierce (registered trademark) may be used.
- a linker compound having a site capable of directly binding to the fluorescent organic dye-encapsulated nanoparticles modified with an organic molecule and a site capable of binding to the molecular target substance can be used.
- sulfo-SMCC Sulfosuccinimidyl 4 [N-maleimidomethyl] -cyclohexane-1-carboxylate: manufactured by Pierce
- antibody-bound fluorescent organic dye-encapsulated nanoparticles can be produced by binding the amino group of fluorescent organic dye-encapsulated nanoparticles modified with aminopropyltriethoxysilane to the mercapto group in the antibody.
- the same procedure can be applied regardless of whether the fluorescent substance is a fluorescent organic dye or a quantum dot. That is, by impregnating a polystyrene nanoparticle having a functional group such as an amino group with a fluorescent organic dye or a quantum dot, a fluorescent substance-containing polystyrene nanoparticle having a functional group can be obtained, and thereafter EDC or sulfo-SMCC is used. In this way, antibody-bound fluorescent substance-encapsulated polystyrene nanoparticles can be produced.
- a method for staining a tissue sample will be described, but a method for preparing a sample to which the staining method described below can be applied is not particularly limited, and a sample prepared by a known method can be used. Further, the application of the quantification method of the present invention is not limited to tissue specimens embedded in paraffin, but can also be applied to specimens such as cells fixed on a substrate.
- the paraffin-embedded tissue specimen is immersed in a container containing xylene to remove paraffin.
- the temperature is not particularly limited, but can be performed at room temperature.
- the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, xylene may be exchanged during the immersion.
- the tissue specimen is immersed in a container containing ethanol to remove xylene.
- the temperature is not particularly limited, but can be performed at room temperature.
- the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. Further, if necessary, ethanol may be exchanged during the immersion.
- the tissue specimen is immersed in a container containing water to remove ethanol.
- the temperature is not particularly limited, but can be performed at room temperature.
- the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. Moreover, you may exchange water in the middle of immersion as needed.
- the activation process of the target biological substance is performed according to a known method.
- the activation conditions are not particularly defined, but as the activation liquid, 0.01 M citrate buffer (pH 6.0), 1 mM EDTA solution (pH 8.0), 5% urea, 0.1 M Tris-HCl buffer, etc. Can be used.
- As the heating device an autoclave, a microwave, a pressure cooker, a water bath, or the like can be used.
- the temperature is not particularly limited, but can be performed at room temperature.
- the temperature can be 50-130 ° C. and the time can be 5-30 minutes.
- the tissue specimen after the activation treatment is immersed in a container containing PBS (Phosphate Buffered Saline) and washed.
- the temperature is not particularly limited, but can be performed at room temperature.
- the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, the PBS may be replaced during the immersion.
- a PBS dispersion of fluorescent particles combined with biological material recognition sites is placed on a tissue specimen and allowed to react with the target biological material.
- staining corresponding to various biological materials becomes possible.
- a PBS dispersion of the respective fluorescent particles may be mixed in advance, or may be separately placed on a tissue specimen sequentially.
- the temperature is not particularly limited, but can be performed at room temperature.
- the reaction time is preferably 30 minutes or more and 24 hours or less. It is preferable to drop a known blocking agent such as BSA-containing PBS before staining with fluorescent particles.
- the stained tissue specimen is immersed in a container containing PBS to remove unreacted fluorescent particles.
- the temperature is not particularly limited, but can be performed at room temperature.
- the immersion time is preferably 3 minutes or longer and 30 minutes or shorter. If necessary, the PBS may be replaced during the immersion. Place the cover glass on the tissue specimen and enclose it. A commercially available encapsulant may be used as necessary.
- HE dyeing is performed before enclosure with a cover glass.
- a microscope image (fluorescence image) is acquired for the stained tissue specimen using the microscope image acquisition device 1A.
- an excitation light source and a fluorescence detection optical filter corresponding to the absorption maximum wavelength and fluorescence wavelength of the fluorescent material used for the staining reagent are selected.
- tissue stained using a staining reagent containing fluorescent particles bound to a biological material recognition site that recognizes a specific biological material hereinafter referred to as HER2 protein in breast cancer tissue, hereinafter referred to as a specific protein.
- the sample will be described as an example of the case where a standard sample is a plurality of types of cultured cells cultured on a substrate such as a slide glass that is commercially available.
- a standard sample is a plurality of types of cultured cells cultured on a substrate such as a slide glass that is commercially available.
- the present invention is not limited to this. This includes specimens that can bind fluorescent particles, such as biotin and antigen whose concentration conditions are known, to which biological substance recognition sites are bound.
- the operator quantifies the specific protein concentration from the cultured cells used as the standard specimen in the present embodiment (step S1).
- the quantification of the specific protein concentration can be performed by any known method such as ELISA, flow cytometry, Western blot, etc., and the specific protein concentration per cell can be calculated.
- specific protein concentration can be quantified from cells dissolved in a predetermined solution, and according to flow cytometry, laser is applied to cells dispersed in a predetermined solution. By performing light scattering and fluorescence measurement using light, it is possible to detect and quantify biomolecules per cell.
- the operator selects, as a standard specimen, cultured cells of the same lot that have the same quality as the cultured cells whose specific protein concentration has been quantified.
- the number of types of standard samples to be selected is arbitrary, but in order to create a calibration curve based on the measurement results of the standard samples and obtain a highly accurate quantitative result, the difference in the specific protein concentration quantified in advance in step S1 is large. It is preferable to use a plurality of types of standard specimens.
- step S2 the operator prepares a formalin-fixed and paraffin-embedded section of the target specimen and the standard specimen (step S2), and adds fluorescent particles to which the HE staining reagent and the biological material recognition site that recognizes the specific protein are bound.
- the target specimen and the standard specimen are each stained under the same conditions using two kinds of staining reagents, ie, staining reagents used as fluorescent labeling materials (step S3).
- Staining under the same conditions means, for example, that one operator performs staining using the same lot of staining reagent, and that the time, temperature and humidity required for each step in staining are substantially constant. It is preferable that one operator sequentially performs the staining operation of the target specimen and the standard specimen in parallel using the same lot of the staining reagent, because the staining conditions can be easily made the same.
- the fluorescence image and the bright field image are acquired from each of the target specimen and the standard specimen according to the following procedures (a1) to (a5) and input to the image processing apparatus 2A for image analysis. Processing is performed (step S4). Image acquisition and image analysis processing from the target sample and the standard sample are performed under the same conditions.
- A1 The operator places the target specimen and the standard specimen stained with the HE staining reagent and the staining reagent containing fluorescent particles on the slide, and places the slide on the slide fixing stage of the microscope image acquisition apparatus 1A.
- A2 Set to the bright field unit, adjust the imaging magnification and focus, and place the observation target area on the tissue in the field of view.
- A3 Shooting is performed by the imaging unit to generate bright field image data, and the image data is transmitted to the image processing apparatus 2A.
- A4) Change the unit to a fluorescent unit.
- A5) Shooting is performed by the imaging means without changing the field of view and the shooting magnification to generate image data of a fluorescent image, and the image data is transmitted to the image processing apparatus 2A.
- performing image acquisition and image analysis processing from the target specimen and the standard specimen under the same conditions specifically refers to image acquisition conditions (for example, exposure time, magnification, Fluorescence image and bright-field image with the same white balance, etc.) are acquired, and cell images and bright spot images are extracted with the same threshold and noise processing conditions set in each step shown in FIG. Indicates to do.
- image acquisition conditions for example, exposure time, magnification, Fluorescence image and bright-field image with the same white balance, etc.
- Step S4 image analysis processing is executed based on the bright field image and the fluorescence image input from the microscope image acquisition apparatus 1A, and an evaluation value obtained by quantitatively evaluating the fluorescence of the fluorescent bright spot per cell is measured.
- fluorescent particles are used as a fluorescent labeling material, and the number of fluorescent particles is used as an evaluation value.
- an integrated value of fluorescent luminance may be used as an evaluation value.
- FIG. 6 shows a detailed flow of the image analysis process in step S4.
- the image analysis process shown in FIG. 6 is executed in cooperation with the control unit 21 and a program stored in the storage unit 25.
- a bright field image is input from the microscope image acquisition apparatus 1A through the communication I / F 24 (step S401)
- a cell region is extracted from the bright field image (steps S402 to S405).
- the bright field image is converted into a monochrome image (step S402).
- FIG. 7A shows an example of a bright field image.
- binarization processing is performed on the monochrome image using a predetermined threshold (step S403).
- noise processing is performed (step S404).
- the noise process can be performed by performing a closing process on the binarized image.
- the closing process is a process in which the contraction process is performed the same number of times after the expansion process is performed.
- the expansion process is a process of replacing a target pixel with white when at least one pixel in the range of n ⁇ n pixels (n is an integer of 2 or more) from the target pixel is white.
- the contraction process is a process of replacing a target pixel with black when at least one pixel in the range of n ⁇ n pixels from the target pixel contains black.
- FIG. 7B shows an example of an image after noise processing. As shown in FIG. 7B, after the noise processing, an image (cell image) from which the cell region is extracted is generated.
- the labeling process is a process for identifying an object in an image by assigning the same label (number) to connected pixels. By the labeling process, each cell can be identified from the image after the noise process and a label can be applied.
- step S406 fluorescence image input process or standard fluorescence image input process
- step S407 fluorescence determination process or standard fluorescence determination process
- a color component corresponding to the emission wavelength of the fluorescent bright spot is extracted from the fluorescent image as shown in FIG. 8A (step S407).
- step S407 for example, when the emission wavelength of the fluorescent particles is 615 nm, only the fluorescent bright spot having the wavelength component is extracted as an image.
- a binarization process is performed on the extracted image using a predetermined threshold value, and a bright spot image from which a bright spot area is extracted is generated (step S408).
- FIG. 8B shows an example of the bright spot image. Note that noise elimination processing such as cell autofluorescence and other unnecessary signal components may be performed before binarization processing, and a low-pass filter such as a Gaussian filter or a high-pass filter such as a second derivative is preferably used.
- step S410 a labeling process is performed, and a label is assigned to each of the extracted bright spot regions.
- step S410 the number of fluorescent particles per each extracted bright spot region is calculated.
- the method for calculating the number of fluorescent particles is arbitrary. For example, the number of fluorescent particles is calculated based on the integrated value of luminance in each bright spot region.
- step S410 addition processing of the cell image (FIG. 7B) and the image from which the bright spot area is extracted (FIG. 8B) is performed (step S411), and the distribution of the bright spot area on the cell is the image processing apparatus.
- the number is displayed on the display unit 23 of 2A, and the number of fluorescent particles per cell area is calculated (step S412).
- step S42 After completion of the process of step S412, the process returns to the process of FIG. 5, and the specific protein concentration of each standard specimen measured in step S1 and the number of fluorescent particles per cell of the standard specimen measured in step S4 are respectively shown on the horizontal axis and A distribution chart showing the correlation by plotting on the vertical axis is created, and a calibration curve based on the distribution chart is created (step S5: correlation calculation step). Next, based on the calibration curve created in step S5, the number of fluorescent particles per cell of the target sample calculated in step S4 is converted into a specific protein concentration (step S6: conversion step).
- the target specimen to be observed and the standard specimen whose specific protein concentration has been measured in advance are prepared by the processing of steps S1 to S2, and the tissue specimen is prepared by the processing of steps S3 to S4.
- staining and image analysis processing are performed on the standard specimen under the same conditions, and the number of fluorescent particles in the target specimen is converted into a specific protein concentration by the processing in steps S5 to S6.
- the number of fluorescent particles in the target specimen is converted into the specific protein concentration based on the measurement result of the standard specimen measured under the same conditions. Even when at least one of them is different, the quantitative results of specific proteins can be compared and evaluated.
- the specific protein amount may be quantified without creating a calibration curve in step S6.
- the specific protein amount is calculated on the assumption that the ratio between the number of fluorescent particles per cell and the specific protein amount in the standard sample matches the ratio between the fluorescent particle number per cell and the specific protein amount in the target sample. be able to.
- the specific protein can be quantified even with only one type of standard sample, and the quantification work is facilitated.
- it is preferable to create a calibration curve based on a plurality of standard samples.
- the calibration curve when the antigen concentration is plotted on the horizontal axis and the evaluation value of the staining level is plotted on the vertical axis is a sigmoid curve when the antigen concentration (horizontal axis) is displayed in logarithm. It has been. Therefore, in the biological material quantification method of the present invention, the calibration curve created in step S6 in FIG. 5 is preferably one in which the distribution of the evaluation value of antigen concentration and fluorescence approximates a sigmoid curve. Furthermore, it is preferable to make a calibration curve by linearly approximating only a portion having a large slope in the created sigmoid curve. The method for selecting the range for linear approximation is arbitrary, but, for example, only a range of specific protein concentrations where the correlation coefficient of the approximate straight line is a predetermined value or more may be used as the calibration curve.
- cultured cell specimens used as standard specimens in this embodiment can be easily obtained in large quantities, a large number of samples can be used to reduce the variation in correlation between specific protein concentrations and the number of fluorescent particles. Therefore, it is suitable as a standard specimen used in the present invention.
- the fluorescent substance used for the staining reagent is described as an example of fluorescent particles in which a plurality of fluorescent substances are accumulated.
- a fluorescent substance in which a biological substance recognition site is bound to one molecule of the fluorescent substance is used as the staining reagent. It may be used.
- fluorescent particles have a high fluorescence luminance per particle, so that they are not easily affected by noise caused by the shooting environment such as room ambient light and the performance of the image acquisition device. Not only the value but also the number of fluorescent particles can be measured and quantified.
- the fluorescent particles hardly cause fading, the fluorescence luminance per particle is not easily affected by the time required for image acquisition (for example, the exposure time of excitation light) and the storage state of the stained specimen. Therefore, when fluorescent particles are used as a staining reagent, there is less error in the fluorescence evaluation value than when a fluorescent material that does not constitute fluorescent particles is used as a staining reagent. There is an advantage that a quantitative result can be obtained. From the above viewpoint, in the present invention, it is preferable to use fluorescent particles as a staining reagent.
- the number of fluorescent particles per cell is measured in step S5.
- the number of fluorescent particles per cell nucleus may be measured, or the measurement target.
- the number of fluorescent particles per area of the image may be measured.
- each color component is extracted using a filter work or the like in step S507, and the processing of steps S508 to S509 is executed for each extracted color component (wavelength component).
- the cell image and the color component are extracted. What is necessary is just to add with the fluorescent particle image produced for every.
- the fluorescent particles may be directly bound to a biological substance recognition site that binds to a specific protein as in the above embodiment, but indirectly through another substance as in the known indirect method in immunostaining. May be combined.
- the specific antibody after reacting a tissue sample with a primary antibody having a specific protein as an antigen, the specific antibody may be stained by reacting a secondary antibody having the primary antibody as an antigen with fluorescent particles bound thereto.
- a fluorescent particle modified with streptavidin is reacted with streptavidin.
- a specific protein may be stained by utilizing the fact that biotin specifically binds to form a complex.
- an HDD or a semiconductor non-volatile memory is used as a computer-readable medium of the program according to the present invention, but the present invention is not limited to this example.
- a portable recording medium such as a CD-ROM can be applied.
- a carrier wave carrier wave is also applied as a medium for providing program data according to the present invention via a communication line.
- This solution was heated to 70 ° C. while stirring on a hot stirrer, and then 0.65 g of melamine resin raw material Nicalak MX-035 (manufactured by Nippon Carbide Industries Co., Ltd.) was added to this solution.
- the mixture was centrifuged at 20000 G for 15 minutes in a centrifuge (Kubota Micro Cooling Centrifuge 3740), and after removing the supernatant, ultrapure water was added and ultrasonically irradiated to redisperse. Centrifugation, supernatant removal, and washing by redispersion in ultrapure water were repeated 5 times.
- the obtained melamine particles were positively charged because the melamine resin itself contains many amino groups in the skeleton.
- the charge of the resin particles was evaluated by analyzing resin components by NMR, IR, etc. and measuring zeta potential.
- the obtained nanoparticles 1 were observed with a scanning electron microscope (SEM; Model S-800, manufactured by Hitachi (registered trademark)). As a result, the average particle size was 150 nm and the coefficient of variation was 12%.
- Step (1) 1 mg of the fluorescent particles 1 was dispersed in 5 mL of pure water. Next, 100 ⁇ L of aminopropyltriethoxysilane aqueous dispersion (LS-3150, manufactured by Shin-Etsu Chemical Co., Ltd.) was added and stirred at room temperature for 12 hours. Step (2): The reaction mixture was centrifuged at 10,000 G for 60 minutes, and the supernatant was removed. Step (3): Ethanol was added to disperse the sediment, followed by centrifugation again. Washing with ethanol and pure water was performed once by the same procedure. When the FT-IR measurement was performed on the resulting amino group-modified fluorescent particles, absorption derived from the amino group could be observed, confirming that the amino group was modified.
- Step (2) The reaction mixture was centrifuged at 10,000 G for 60 minutes, and the supernatant was removed.
- Step (3) Ethanol was added to disperse the sediment, followed by centrifugation again. Washing with ethanol and pure water was performed once by the
- Step (4) The amino group-modified fluorescent particles obtained in step (3) were adjusted to 3 nM using PBS containing 2 mM of EDTA (ethylenediaminetetraacetic acid).
- Step (6) The reaction mixture was centrifuged at 10,000 G for 60 minutes, and the supernatant was removed.
- Step (7) PBS containing 2 mM of EDTA was added, the precipitate was dispersed, and centrifuged again. The washing
- Step (8) When 100 ⁇ g of anti-Ki67 antibody was dissolved in 100 ⁇ L of PBS, 1 M dithiothreitol (DTT) was added and reacted for 30 minutes.
- Step (10) Using the fluorescent particles as a starting material, the particle dispersion obtained in step (7) and the reduced anti-Ki67 antibody solution obtained in step (9) were mixed in PBS and allowed to react for 1 hour. .
- Step (11) 4 ⁇ L of 10 mM mercaptoethanol was added to stop the reaction.
- A-1) Preparation of Target Specimen and Standard Specimen Three spots (a, b, c) were selected from the breast cancer tissue array as target specimens, and fixed, dehydrated, embedded and sliced sections were used.
- the expression level of Ki67 protein in five types of commercially available cell lines (CRL1500, NDA-MB175, COLO201, Hela, NDA-MB231) was measured using ELISA kit manufactured by Invitrogen (Human HER2 (Total) kit, No. KHO0701), and a cultured cell line of the same lot as the above five types of cultured cell lines was used as a standard specimen.
- Step (1) The target specimen and the standard specimen were immersed in a container containing xylene for 30 minutes. The xylene was changed three times during the process.
- Step (2) The target specimen and the standard specimen were immersed in a container containing ethanol for 30 minutes. The ethanol was changed three times during the process.
- Step (3) The target specimen and the standard specimen were immersed in a container containing water for 30 minutes. The water was changed three times along the way.
- Step (4) The target specimen and the standard specimen were immersed in a 10 mM citrate buffer (pH 6.0) for 30 minutes.
- A-3) Acquisition of microscope image Microscope images (bright field image and fluorescence image) were acquired for the target specimen and the standard specimen.
- an upright microscope Axio Imager M2 manufactured by Carl Zeiss was used, and the objective lens was set to 20 times.
- excitation light having a wavelength of 580 nm is irradiated with an exposure time of 200 ms to form an image of fluorescence having a wavelength of 610 nm emitted from a tissue section, and a microscope image (image) is captured by a microscope installation camera (monochrome). Data).
- the camera has a pixel size of 6.4 ⁇ m ⁇ 6.4 ⁇ m, a vertical pixel count of 1040, and a horizontal pixel count of 1388 (imaging area 8.9 mm ⁇ 6.7 mm). Note that the fluorescence images of the target specimen and the standard specimen were acquired by the same operator using the same apparatus under the same conditions almost at the same time.
- (A-4) Calculation of the number of fluorescent particles per cell
- the image analysis processing of FIG. 6 is executed on the microscope image of the target specimen and the standard specimen acquired in (A-3), and 1 cell is used as the fluorescence evaluation value.
- the number of fluorescent particles per unit was calculated.
- a binarized image is created based on preset upper and lower thresholds, and the bright spot measurement software “G-count” manufactured by J.A. was used to count the number of fluorescent particles. Thereafter, the bright field image acquired in (A-3) and the fluorescence image were superimposed, the number of bright spots in the cell region was calculated, and the number of fluorescent particles per cell in the target specimen and the standard specimen was calculated.
- the number of fluorescent particles per cell in the target specimen (the number of fluorescent particles / cell) is referred to as Comparative Example 1.
- A-5 Quantification of expression level of Ki67 protein per cell As shown in FIG. 9, the expression level of Ki67 protein measured in advance from a cultured cell line of the same lot as the standard sample is plotted on the horizontal axis (A-4 A distribution map with the vertical axis representing the number of fluorescent particles per cell in the standard sample calculated in (1) was created, and the created distribution was linearly approximated to create a calibration curve as shown by the dotted line in FIG. Next, using the calibration curve, the number of fluorescent particles per cell in the target specimen was converted to Ki67 protein concentration (ng / ml) per cell in the target specimen, and Example 1 was obtained.
- Ki67 protein concentration ng / ml
- the above (A) was used except that a staining reagent diluted with a fluorescent particle concentration of 0.06 nM was used.
- the number of fluorescent particles per cell in the target specimen and the standard specimen was quantified.
- the number of fluorescent particles per cell in the target specimen (the number of fluorescent particles / cell) is Comparative Example 2, and the number of fluorescent particles per cell in the target specimen is the Ki67 protein concentration per cell in the target specimen (ng / ml).
- Example 2 was converted to.
- As the target specimen among the sections prepared from the three spots (ac) of the breast cancer tissue array described in (A-1) above, for staining and quantification of Ki67 protein concentration in (A) Sections adjacent to each of the three sections used were used.
- FIG. 9 shows a calibration curve created in the quantitative steps of (A) and (B).
- the slope of the calibration curve is that the concentration of the fluorescent particles is 0.02 nm. While the time was about 0.69, when the fluorescent particle concentration was 0.06 nm, it was about 1.85, and there was a difference of about three times in the slope.
- the quantitative results of Examples 1 and 2 and Comparative Examples 1 and 2 are shown in Table 1.
- the exposure time at the time of acquiring the fluorescent image was about 1 ⁇ 2 times. Even in this case, the quantitative result is 0.85 to 1.08 times, and by performing correction based on the calibration curve using the method of the present invention, the difference in the quantitative result due to the difference in exposure time during fluorescent image acquisition is reduced. did.
- the present invention is characterized in that a specific biological substance in a tissue specimen can be accurately quantified, and can be particularly suitably used for generating highly accurate pathological diagnosis information.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Quality & Reliability (AREA)
- Radiology & Medical Imaging (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Optics & Photonics (AREA)
- Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量する生体物質定量方法において、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力工程と、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量工程と、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力工程と同一条件で入力する標準蛍光画像入力工程と、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量工程と同一条件で算出する標準蛍光定量工程と、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出工程と、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算工程と、
を有することを特徴とする。
前記相関関係算出工程において、前記標準標本における前記生体物質の発現量に対する前記標準蛍光画像の蛍光輝点の評価値を示す検量線を作成し、
前記換算工程において、前記検量線に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算することを特徴とする。
前記標準標本が基材上に培養された培養細胞であることを特徴とする。
前記生体物質がタンパク質であることを特徴とする。
前記染色試薬が前記蛍光物質を複数集積した蛍光粒子を含むことを特徴とする。
蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量する病理診断支援システムであって、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力手段と、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量手段と、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力手段と同一条件で入力する標準蛍光画像入力手段と、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量手段と同一条件で算出する標準蛍光定量手段と、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出手段と、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算手段と、
を備えることを特徴とする。
蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量するコンピュータを、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力手段、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量手段、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力手段と同一条件で入力する標準蛍光画像入力手段、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量手段と同一条件で算出する標準蛍光定量手段、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出手段、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算手段、
として機能させることを特徴とする。
図1に、本発明の生体物質定量方法を用いた病理診断支援システム100の全体構成例を示す。病理診断支援システム100は、所定の染色試薬で染色された、観察対象の標本(以後、「対象標本」と呼ぶ)、及び予め特定の生体物質濃度を定量した標本(以後、「標準標本」と呼ぶ)の顕微鏡画像を取得し、取得された顕微鏡画像を解析することにより、対象標本における特定の生体物質の発現を定量的に表す特徴量を出力するシステムである。
顕微鏡画像取得装置1Aは、照射手段、結像手段、撮像手段、通信I/F等を備えて構成されている。照射手段は、光源、フィルター等により構成され、スライド固定ステージに載置されたスライド上の標本に光を照射する。結像手段は、接眼レンズ、対物レンズ等により構成され、照射した光によりスライド上の標本から発せられる透過光、反射光、又は蛍光を結像する。撮像手段は、CCD(Charge Coupled Device)センサー等を備え、結像手段により結像面に結像される像を撮像して顕微鏡画像のデジタル画像データを生成する顕微鏡設置カメラである。通信I/Fは、生成された顕微鏡画像の画像データを画像処理装置2Aに送信する。本実施の形態において、顕微鏡画像取得装置1Aは、明視野観察に適した照射手段及び結像手段を組み合わせた明視野ユニット、蛍光観察に適した照射手段及び結像手段を組み合わせた蛍光ユニットが備えられており、ユニットを切り替えることにより明視野/蛍光を切り替えることが可能である。
図2に、画像処理装置2Aの機能構成例を示す。図2に示すように、画像処理装置2Aは、制御部21、操作部22、表示部23、通信I/F24、記憶部25等を備えて構成され、各部はバス26を介して接続されている。
その他、画像処理装置2Aは、LANアダプターやルーター等を備え、LAN等の通信ネットワークを介して外部機器と接続される構成としてもよい。
明視野画像は、H(ヘマトキシリン)染色試薬、HE(ヘマトキシリン-エオジン)染色試薬を用いて染色された標本を、顕微鏡画像取得装置1Aにおいて明視野で拡大結像及び撮影することにより得られる顕微鏡画像であって、当該標本における細胞の形態を表す細胞形態画像である。ヘマトキシリンは青紫色の色素であり、細胞核、骨組織、軟骨組織の一部、漿液成分など(好塩基性の組織等)を染色する。エオジンは赤~ピンク色の色素であり、細胞質、軟部組織の結合組織、赤血球、線維素、内分泌顆粒など(好酸性の組織等)を染色する。図3に、HE染色を行った標本を撮影した明視野画像の一例を示す。
ここで、蛍光画像の取得方法について、この蛍光画像の取得に際して用いられる染色試薬及び染色試薬による標本の染色方法も含めて詳細に説明する。
蛍光画像の取得のための染色試薬に用いられる蛍光物質としては、蛍光有機色素及び量子ドット(半導体粒子)を挙げることができる。200~700nmの範囲内の波長の紫外~近赤外光により励起されたときに、400~1100nmの範囲内の波長の可視~近赤外光の発光を示すことが好ましい。
本実施の形態において、蛍光画像の取得のための染色試薬に用いられる蛍光物質は、蛍光物質が複数集積された蛍光物質内包ナノ粒子(以下、蛍光粒子と呼ぶ)を用いることができる。蛍光粒子とは、蛍光物質がナノ粒子内部に分散されたものをいい、蛍光物質とナノ粒子自体とが化学的に結合していても、結合していなくてもよい。ナノ粒子を構成する素材は特に限定されるものではなく、ポリスチレン、ポリ乳酸、シリカ、メラミン等を挙げることができる。
量子ドットは必要に応じて、有機ポリマー等により表面処理が施されているものを用いてもよい。例えば、表面カルボキシ基を有するCdSe/ZnS(インビトロジェン社製)、表面アミノ基を有するCdSe/ZnS(インビトロジェン社製)等が挙げられる。
平均粒径は、走査型電子顕微鏡(SEM)を用いて撮影した電子顕微鏡写真から粒子の断面積を計測し、各計測値を円の面積としたときの円の直径を粒径とする。本願においては、1000個の粒子の粒径を計測し、その算術平均を平均粒径とした。
本実施の形態に係る生体物質認識部位とは、目的とする生体物質と特異的に結合及び/又は反応する部位である。目的とする生体物質は、それと特異的に結合する物質が存在するものであれば特に限定されるものではないが、代表的にはタンパク質(ペプチド)および核酸(オリゴヌクレオチド、ポリヌクレオチド)、抗体等が挙げられる。したがって、そのような目的とする生体物質に結合する物質としては、前記タンパク質を抗原として認識する抗体やそれに特異的に結合する他のタンパク質等、および前記核酸にハイブリタイズする塩基配列を有する核酸等が挙げられる。具体的には、細胞表面に発現するタンパク質であるHER2に特異的に結合する抗HER2抗体、細胞核に発現する細胞増殖のマーカーであるKi67タンパク質に特異的に結合するKi67抗体、細胞核に発現するエストロゲン受容体(ER)に特異的に結合する抗ER抗体、細胞骨格を形成するアクチンに特異的に結合する抗アクチン抗体、等があげられる。中でも抗HER2抗体又は抗ER抗体又は抗Ki67抗体を蛍光粒子に結合させたものは、乳癌の投薬選定に用いることができ、好ましい。
以下、組織標本の染色方法について述べるが、以下に説明する染色方法が適用できる標本の作製法は特に限定されず、公知の方法により作製されたものを用いることができる。
また、本発明の定量方法の適用はパラフィン包埋された組織標本に限定されるものではなく、基板上に固定した細胞等の標本にも適用可能である。
パラフィン包埋された組織標本を、キシレンを入れた容器に浸漬させ、パラフィンを除去する。温度は特に限定されるものではないが、室温で行うことができる。浸漬時間は、3分以上30分以下であることが好ましい。また、必要により浸漬途中でキシレンを交換してもよい。
次いで、エタノールを入れた容器に組織標本を浸漬させ、キシレンを除去する。温度は特に限定されるものではないが、室温で行うことができる。浸漬時間は、3分以上30分以下であることが好ましい。また、必要により浸漬途中でエタノールを交換してもよい。
次いで、水を入れた容器に組織標本を浸漬させ、エタノールを除去する。温度は特に限定されるものではないが、室温で行うことができる。浸漬時間は、3分以上30分以下であることが好ましい。また、必要により浸漬途中で水を交換してもよい。
公知の方法にならい、目的とする生体物質の賦活化処理を行う。賦活化条件に特に定めはないが、賦活液としては、0.01M クエン酸緩衝液(pH6.0)、1mM EDTA溶液(pH8.0)、5% 尿素、0.1M トリス塩酸緩衝液等を用いることができる。加熱機器は、オートクレーブ、マイクロウェーブ、圧力鍋、ウォーターバス等を用いることができる。温度は特に限定されるものではないが、室温で行うことができる。温度は50-130℃、時間は5-30分で行うことができる。
次いで、PBS(Phosphate Buffered Saline:リン酸緩衝生理食塩水)を入れた容器に、賦活化処理後の組織標本を浸漬させ、洗浄を行う。温度は特に限定されるものではないが、室温で行うことができる。浸漬時間は、3分以上30分以下であることが好ましい。また、必要により浸漬途中でPBSを交換してもよい。
生体物質認識部位が結合された蛍光粒子のPBS分散液を組織標本に載せ、目的とする生体物質と反応させる。蛍光粒子と結合させる生体物質認識部位を変えることにより、さまざまな生体物質に対応した染色が可能となる。数種類の生体物質認識部位が結合された蛍光粒子を用いる場合には、それぞれの蛍光粒子のPBS分散液を予め混合しておいてもよいし、別々に順次組織標本に載せてもよい。
温度は特に限定されるものではないが、室温で行うことができる。反応時間は、30分以上24時間以下であることが好ましい。
蛍光粒子による染色を行う前に、BSA含有PBS等、公知のブロッキング剤を滴下することが好ましい。
なお、HE染色試薬を用いて染色を行う場合、カバーガラスによる封入前にHE染色を行う。
染色した組織標本に対し、顕微鏡画像取得装置1Aを用いて、顕微鏡画像(蛍光画像)を取得する。顕微鏡画像取得装置1Aにおいて、染色試薬に用いた蛍光物質の吸収極大波長及び蛍光波長に対応した励起光源及び蛍光検出用光学フィルターを選択する。
以下、病理診断支援システム100を用いて生体物質の定量(上記説明した染色、画像の取得及び解析を含む)を行う動作について、図5のフローチャートを用いて説明する。ここでは、特定の生体物質(ここでは、乳癌組織におけるHER2タンパク質とする。以下、特定タンパク質と呼ぶ。)を認識する生体物質認識部位が結合した蛍光粒子を含む染色試薬を用いて染色された組織標本を対象標本とし、市販されているスライドガラス等の基材上に培養された複数種類の培養細胞を標準標本とする場合を例にとり説明するが、これに限定されるものではなく、生体物質の濃度条件が把握されたビオチンや抗原など、生体物質認識部位が結合した蛍光粒子の結合可能な標本を含む。
操作者は特定タンパク質濃度を定量した培養細胞と均一な品質である同一ロットの培養細胞を標準標本として選択する。選択する標準標本の種類数は任意であるが、標準標本の計測結果に基づく検量線を作成して精度の高い定量結果を得るために、ステップS1において予め定量された特定タンパク質濃度の差が大きな、複数種類の標準標本を用いることが好ましい。
同一条件で染色するとは、例えば、一人の操作者が、同じロットの染色試薬を用いて染色を行い、かつ、染色における各工程の所要時間及び温度及び湿度がほぼ一定であることを示す。一人の操作者が、同じロットの染色試薬を用いて、対象標本及び標準標本の染色作業を並行して順次行うこととすれば、染色条件を容易に同一にすることができるため好ましい。
(a1)操作者は、HE染色試薬と蛍光粒子を含む染色試薬とにより染色された対象標本及び標準標本をスライドに載置し、そのスライドを顕微鏡画像取得装置1Aのスライド固定ステージに設置する。
(a2)明視野ユニットに設定し、撮影倍率、ピントの調整を行い、組織上の観察対象の領域を視野に納める。
(a3)撮像手段で撮影を行って明視野画像の画像データを生成し、画像処理装置2Aに画像データを送信する。
(a4)ユニットを蛍光ユニットに変更する。
(a5)視野及び撮影倍率を変えずに撮像手段で撮影を行って蛍光画像の画像データを生成し、画像処理装置2Aに画像データを送信する。
まず、通信I/F24により顕微鏡画像取得装置1Aからの明視野画像が入力されると(ステップS401)、明視野画像から細胞領域の抽出が行われる(ステップS402~ステップS405)。
次いで、モノクロ画像に対し予め定められた閾値を用いて二値化処理が施される(ステップS403)。
ステップS407では、たとえば、蛍光粒子の発光波長が615nmである場合には、その波長成分を有する蛍光輝点のみが画像として抽出される。次いで、抽出された画像に予め定められた閾値を用いて二値化処理が施され、輝点領域が抽出された輝点画像が生成される(ステップS408)。図8Bに、輝点画像の一例を示す。
なお、二値化処理の前に細胞自家蛍光や他の不要信号成分等のノイズ除去処理が施されてもよく、ガウシアンフィルタ等のローパスフィルタや二次微分等のハイパスフィルタが好ましく用いられる。
次いで、抽出された各輝点領域当たりの蛍光粒子数が算出される(ステップS410)。蛍光粒子数の算出方法は任意であり、例えば、各輝点領域内の輝度の積算値に基づいて蛍光粒子数を算出する。
次いで、ステップS5で作成された検量線に基づいて、ステップS4で算出された対象標本の1細胞当たりの蛍光粒子数が特定タンパク質濃度に換算される(ステップS6:換算工程)。
しかし、蛍光粒子は、一粒子当たりの蛍光輝度が大きいため、部屋の環境光等の撮影環境に起因するノイズや、画像取得装置の性能の影響を受けにくく、また、蛍光画像から、蛍光の輝度値だけでなく蛍光粒子の数を計測して定量可能である。また、蛍光粒子は褪色を起こしにくいため、1粒子当たりの蛍光輝度は、画像の取得に要した時間(例えば、励起光の露光時間)や染色した標本の保存状態の影響を受けにくい。従って、蛍光粒子を染色試薬として用いた場合は、蛍光粒子を構成していない蛍光物質を染色試薬として用いた場合と比較して、蛍光の評価値の誤差がより少ないため、精度の高い生体物質定量結果を得ることができるという利点がある。以上のような観点から、本発明においては、蛍光粒子を染色試薬として用いることが好ましい。
かかる場合、ステップS507においてフィルターワーク等を用いてそれぞれの色成分を抽出し、その抽出した色成分(波長成分)ごとにステップS508~S509の処理を実行し、ステップS511において、細胞画像と色成分毎に作成された蛍光粒子画像とを加算すればよい。
(A)蛍光粒子濃度が0.02nMの染色試薬を用いた定量
(A-0)染色試薬の作製
[蛍光物質内包メラミンナノ粒子の作製]
蛍光色素として赤色発光色素であるSulfo Rhodamine 101(シグマアルドリッチ社製)14.4mgを水22mLに加えて溶解させた。その後、この溶液に乳化重合用乳化剤のエマルジョン(登録商標)430(ポリオキシエチレンオレイルエーテル、花王社製)の5%水溶液を2mL加えた。この溶液をホットスターラー上で撹拌しながら70℃まで昇温させた後、この溶液にメラミン樹脂原料ニカラックMX-035(日本カーバイド工業社製)を0.65g加えた。
具体的には、遠心分離機(クボタ社製マイクロ冷却遠心機3740)にて20000Gで15分間、遠心分離し、上澄み除去後、超純水を加えて超音波照射して再分散した。遠心分離、上澄み除去および超純水への再分散による洗浄を5回繰り返した。得られたメラミン粒子はメラミン樹脂自体が骨格に多くのアミノ基を含むことから、プラス電荷となった。樹脂粒子の電荷の評価は、NMRやIR等による樹脂成分分析と、ゼータ電位測定により行なった。
下記工程(1)~(12)の方法により、蛍光粒子に対して抗Ki67抗体を結合させた。
工程(1):1mgの蛍光粒子1を純水5mLに分散させた。次いで、アミノプロピルトリエトキシシラン水分散液(LS-3150、信越化学工業社製)100μLを添加し、室温で12時間撹拌した。
工程(2):反応混合物を10000Gで60分遠心分離を行い、上澄みを除去した。
工程(3):エタノールを加え、沈降物を分散させ、再度遠心分離を行った。同様の手順でエタノールと純水による洗浄を1回ずつ行った。
得られたアミノ基修飾した蛍光粒子のFT-IR測定を行ったところ、アミノ基に由来する吸収が観測でき、アミノ基修飾されたことが確認できた。
工程(5):工程(4)で調整した溶液に、最終濃度10mMとなるようSM(PEG)12(サーモサイエンティフィック社製、succinimidyl-[(N-maleomidopropionamid)-dodecaethyleneglycol」ester)を混合し、1時間反応させた。
工程(6):反応混合液を10000Gで60分遠心分離を行い、上澄みを除去した。
工程(7):EDTAを2mM含有したPBSを加え、沈降物を分散させ、再度遠心分離を行った。同様の手順による洗浄を3回行った。最後に500μLのPBSを用いて再分散させた。
工程(9):反応混合物についてゲルろ過カラムにより過剰のDTTを除去し、還元化抗Ki67抗体溶液を得た。
工程(11):10mMメルカプトエタノール4μLを添加し、反応を停止させた。
工程(12):反応混合物を10000Gで60分遠心分離を行い、上澄みを除去した後、EDTAを2mM含有したPBSを加え、沈降物を分散させ、再度遠心分離を行った。同様の手順による洗浄を3回行った。最後に500μLのPBSを用いて再分散させ、Ki67抗体が結合された蛍光粒子を得た。
対象標本として、乳癌組織アレイから3つのスポット(a、b、c)を選択し、固定、脱水、包埋、薄切した切片を用いた。
標準標本としては、市販の5種類の培養細胞株(CRL1500、NDA-MB175、COLO201、Hela、NDA-MB231)のKi67タンパク質の発現量を、インビトロジェン社製のELISAキット(Human HER2(Total)kit,No.KHO0701)を用いて測定し、上記の5種類の培養細胞株と同一ロットの培養細胞株を標準標本とした。
続いて、対象標本及び標準標本を、下記工程(1)~(11)の工程によって免疫染色した。なお、対象標本及び標準標本の免疫染色は、同一の操作者が並行して作業することにより、ほぼ同時に、同一条件で行った。
工程(1):キシレンを入れた容器に対象標本及び標準標本を30分浸漬させた。途中3回キシレンを交換した。
工程(2):エタノールを入れた容器に対象標本及び標準標本を30分浸漬させた。途中3回エタノールを交換した。
工程(3):水を入れた容器に対象標本及び標準標本を30分浸漬させた。途中3回水を交換した。
工程(4):10mMクエン酸緩衝液(pH6.0)に対象標本及び標準標本を30分浸漬させた。
工程(5):121度で10分オートクレーブ処理を行った。
工程(6):PBSを入れた容器に、オートクレーブ処理後の対象標本及び標準標本を30分浸漬させた。
工程(7):1%BSA含有PBSを対象標本及び標準標本に載せて、1時間放置した。
工程(8):1%BSA含有PBSで蛍光粒子濃度0.02nMに希釈した染色試薬を、それぞれ対象標本及び標準標本に載せて3時間放置した。
工程(9):PBSを入れた容器に、染色後の対象標本及び標準標本をそれぞれ30分浸漬させた。
工程(10):4%中性パラホルムアルデヒド溶液で10分間固定処理した後、ヘマトキシリン染色を行った。
工程(11):Merck Chemicals社製Aquatexを滴下後、カバーガラスを載せ封入した。
対象標本及び標準標本について、顕微鏡画像(明視野画像及び蛍光画像)を取得した。
顕微鏡として、カールツアイス社製正立顕微鏡Axio Imager M2を用い、対物レンズを20倍に設定した。蛍光画像の取得にあたっては、580nmの波長を有する励起光を露光時間200msで照射して、組織切片から発せられる610nmの波長を有する蛍光を結像し、顕微鏡設置カメラ(モノクロ)により顕微鏡画像(画像データ)を取得した。上記カメラは画素サイズ6.4μm×6.4μm、縦画素数1040個、横画素数1388個(撮像領域8.9mm×6.7mm)を有している。
なお、対象標本及び標準標本の蛍光画像は、同一の操作者が同一の装置を用いて、ほぼ同時に、同一条件で取得した。
(A-3)で取得した対象標本及び標準標本の顕微鏡画像に、図6の画像解析処理を実行し、蛍光の評価値として、1細胞当たりの蛍光粒子数を算出した。蛍光粒子数の算出は、予め設定された上限閾値および下限閾値に基づいて2値化画像を作成し、作成された2値化画像から、ジーオングストローム社製の輝点計測ソフト「G-count」を用いて蛍光粒子数を計測した。その後、(A-3)で取得した明視野画像と蛍光画像とを重ね合わせ、細胞領域内の輝点数を算出して、対象標本及び標準標本における1細胞当たりの蛍光粒子数を算出した。対象標本における1細胞当たりの蛍光粒子数(蛍光粒子数/細胞)を、比較例1とする。
図9に示されるように、標準標本と同一ロットの培養細胞株から予め計測されたKi67タンパク質の発現量を横軸、(A-4)で算出した標準標本における1細胞当たりの蛍光粒子数を縦軸とした分布図を作成し、作成した分布を線形近似して、図9において点線で示されるような検量線を作成した。次いで、当該検量線を用いて、対象標本における1細胞当たりの蛍光粒子数を、対象標本における1細胞当たりのKi67タンパク質濃度(ng/ml)に換算して実施例1とした。
上記(A-2)の工程(8)において、蛍光粒子濃度を0.06nMに希釈した染色試薬を用いた他は上記(A)と同じ工程によって、対象標本及び標準標本における1細胞当たりの蛍光粒子数を定量した。対象標本における1細胞当たりの蛍光粒子数(蛍光粒子数/細胞)を、比較例2とし、対象標本における1細胞当たりの蛍光粒子数を対象標本における1細胞当たりのKi67タンパク質濃度(ng/ml)に換算したものを実施例2とした。
なお、対象標本としては、上記(A-1)に記載されている乳癌組織アレイの3つのスポット(a~c)から作成された切片のうち、(A)で染色及びKi67タンパク質濃度の定量に用いた3つの切片にそれぞれ隣接した切片を用いた。
図9に、上記(A)及び(B)の定量工程において作成された検量線を示す。5種類の標準標本において、ELISA法によって定量されたKi67タンパク質濃度に対する蛍光画像から算出された蛍光粒子数を線形近似して検量線とすると、検量線の傾きは、蛍光粒子濃度が0.02nmの時は約0.69であったのに対し、蛍光粒子濃度が0.06nmの時は約1.85であり、傾きに約3倍の差があった。
実施例1、2及び比較例1、2の定量結果を表1に示す。
(D)蛍光画像取得時の露光時間が100msの場合の定量
上記(A-1)(A-2)で準備及び染色した標本を用いて、上記(A-3)において、励起光の露光時間を100msにした他は上記(A-3)~(A-5)と同じ工程によって、対象標本及び標準標本における1細胞当たりの蛍光粒子数を定量した。対象標本における1細胞当たりの蛍光粒子数(蛍光粒子数/細胞)を、比較例3とし、対象標本における1細胞当たりの蛍光粒子数を対象標本における1細胞当たりのKi67タンパク質濃度(ng/ml)に換算したものを実施例3とした。
実施例1と3、及び比較例1と3における定量結果を表2に示す。
2A 画像処理装置
3A ケーブル
21 制御部(蛍光定量手段、標準蛍光定量手段、相関関係算出手段、換算手段)
22 操作部
23 表示部
24 通信I/F(蛍光画像入力手段、標準蛍光画像入力手段)
25 記憶部
26 バス
100 病理診断支援システム
Claims (7)
- 蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量する生体物質定量方法において、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力工程と、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量工程と、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力工程と同一条件で入力する標準蛍光画像入力工程と、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量工程と同一条件で算出する標準蛍光定量工程と、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出工程と、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算工程と、
を有することを特徴とする生体物質定量方法。 - 前記相関関係算出工程において、前記標準標本における前記生体物質の発現量に対する前記標準蛍光画像の蛍光輝点の評価値を示す検量線を作成し、
前記換算工程において、前記検量線に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算することを特徴とする請求項1に記載の生体物質定量方法。 - 前記標準標本が基材上に培養された培養細胞であることを特徴とする請求項1又は2に記載の生体物質定量方法。
- 前記生体物質がタンパク質であることを特徴とする請求項1~3の何れか一項に記載の生体物質定量方法。
- 前記染色試薬が前記蛍光物質を複数集積した蛍光粒子を含むことを特徴とする請求項1~4の何れか一項に記載の生体物質定量方法。
- 蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量する病理診断支援システムであって、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力手段と、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量手段と、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力手段と同一条件で入力する標準蛍光画像入力手段と、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量手段と同一条件で算出する標準蛍光定量手段と、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出手段と、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算手段と、
を備えることを特徴とする病理診断支援システム。 - 蛍光物質を用いて特定の生体物質を染色可能な染色試薬により染色された標本における前記生体物質の発現量を定量するコンピュータを、
前記標本における前記生体物質の発現を蛍光輝点で表す蛍光画像を入力する蛍光画像入力手段、
前記蛍光画像から前記蛍光輝点を定量的に評価した評価値を算出する蛍光定量手段、
予め前記生体物質の発現量が計測された標準標本において、前記標本の染色と同一条件の染色に基づく前記生体物質の発現を蛍光輝点で表す標準蛍光画像を、前記蛍光画像入力手段と同一条件で入力する標準蛍光画像入力手段、
前記標準蛍光画像から前記蛍光輝点を定量的に評価した評価値を前記蛍光定量手段と同一条件で算出する標準蛍光定量手段、
前記標準標本における前記生体物質の発現量及び前記標準蛍光画像の蛍光輝点の評価値の相関関係を算出する相関関係算出手段、
前記相関関係に基づいて、前記蛍光画像の蛍光輝点の評価値を前記標本における前記生体物質の発現量に換算する換算手段、
として機能させることを特徴とするプログラム。
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/549,006 US10234391B2 (en) | 2015-02-10 | 2015-02-10 | Biological substance quantitation method, pathological diagnosis support system and recording medium storing computer readable program |
EP15881936.7A EP3258264B1 (en) | 2015-02-10 | 2015-02-10 | Biological substance quantitation method |
PCT/JP2015/053679 WO2016129061A1 (ja) | 2015-02-10 | 2015-02-10 | 生体物質定量方法、病理診断支援システム及びプログラム |
JP2016574558A JP6520961B2 (ja) | 2015-02-10 | 2015-02-10 | 生体物質定量方法、病理診断支援システム及びプログラム |
US16/256,224 US10309900B1 (en) | 2015-02-10 | 2019-01-24 | Biological substance quantitation method, pathological diagnosis support system and recording medium storing computer readable program |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2015/053679 WO2016129061A1 (ja) | 2015-02-10 | 2015-02-10 | 生体物質定量方法、病理診断支援システム及びプログラム |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/549,006 A-371-Of-International US10234391B2 (en) | 2015-02-10 | 2015-02-10 | Biological substance quantitation method, pathological diagnosis support system and recording medium storing computer readable program |
US16/256,224 Continuation US10309900B1 (en) | 2015-02-10 | 2019-01-24 | Biological substance quantitation method, pathological diagnosis support system and recording medium storing computer readable program |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016129061A1 true WO2016129061A1 (ja) | 2016-08-18 |
Family
ID=56615216
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2015/053679 WO2016129061A1 (ja) | 2015-02-10 | 2015-02-10 | 生体物質定量方法、病理診断支援システム及びプログラム |
Country Status (4)
Country | Link |
---|---|
US (2) | US10234391B2 (ja) |
EP (1) | EP3258264B1 (ja) |
JP (1) | JP6520961B2 (ja) |
WO (1) | WO2016129061A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019078230A1 (ja) | 2017-10-19 | 2019-04-25 | コニカミノルタ株式会社 | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム |
WO2021005904A1 (ja) * | 2019-07-09 | 2021-01-14 | ソニー株式会社 | 情報処理装置およびプログラム |
WO2021157397A1 (ja) * | 2020-02-06 | 2021-08-12 | ソニーグループ株式会社 | 情報処理装置及び情報処理システム |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10809167B2 (en) * | 2010-08-30 | 2020-10-20 | Konica Minolta, Inc. | Tissue staining method with staining agent containing particle holding plural phosphors |
EP3483592B1 (en) * | 2016-07-05 | 2020-07-22 | Konica Minolta, Inc. | Biological material quantifying method, image processing device, pathological diagnosis support system and program |
US10444137B2 (en) | 2018-01-23 | 2019-10-15 | Cbrn International, Ltd. | Bioaerosol detector having safeguards |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013002158A1 (ja) * | 2011-06-27 | 2013-01-03 | 株式会社日立製作所 | 細胞培養装置および細胞培養方法 |
WO2013146694A1 (ja) * | 2012-03-28 | 2013-10-03 | コニカミノルタ株式会社 | 生体物質の検出方法 |
WO2013146843A1 (ja) * | 2012-03-30 | 2013-10-03 | コニカミノルタ株式会社 | 医用画像処理装置及びプログラム |
WO2015002082A1 (ja) * | 2013-07-03 | 2015-01-08 | コニカミノルタ株式会社 | 画像処理装置、病理診断支援システム、画像処理プログラム及び病理診断支援方法 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5123660B2 (ja) * | 2005-03-30 | 2013-01-23 | オリンパス株式会社 | 測定装置 |
JP5307539B2 (ja) * | 2006-05-31 | 2013-10-02 | オリンパス株式会社 | 生体試料撮像方法および生体試料撮像装置 |
US20130230866A1 (en) * | 2010-09-17 | 2013-09-05 | Tohoku University | Method for Determining Effectiveness of Medicine Containing Antibody as Component |
WO2012078138A1 (en) * | 2010-12-07 | 2012-06-14 | Wei-Sing Chu | Cell array quality control device for pathological analysis |
US20140329716A1 (en) * | 2011-09-02 | 2014-11-06 | Emory University | Devices having a calibration control region, systems and methods for immunohistochemical analyses |
JP5906623B2 (ja) | 2011-09-09 | 2016-04-20 | コニカミノルタ株式会社 | 生体物質発現レベル評価システム |
WO2013146841A1 (ja) * | 2012-03-30 | 2013-10-03 | コニカミノルタ株式会社 | 医用画像処理装置及びプログラム |
US20130338014A1 (en) * | 2012-04-05 | 2013-12-19 | Vala Sciences, Inc. | Calibration Standards For Digital Histocytometry |
US20130338016A1 (en) * | 2012-04-17 | 2013-12-19 | Vala Sciences, Inc. | Method For Integrated Pathology Diagnosis And Digital Biomarker Pattern Analysis |
EP2972227B1 (en) * | 2013-03-12 | 2020-05-06 | Ventana Medical Systems, Inc. | Digitally enhanced microscopy for multiplexed histology |
US8995740B2 (en) * | 2013-04-17 | 2015-03-31 | General Electric Company | System and method for multiplexed biomarker quantitation using single cell segmentation on sequentially stained tissue |
-
2015
- 2015-02-10 JP JP2016574558A patent/JP6520961B2/ja active Active
- 2015-02-10 WO PCT/JP2015/053679 patent/WO2016129061A1/ja active Application Filing
- 2015-02-10 EP EP15881936.7A patent/EP3258264B1/en active Active
- 2015-02-10 US US15/549,006 patent/US10234391B2/en active Active
-
2019
- 2019-01-24 US US16/256,224 patent/US10309900B1/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013002158A1 (ja) * | 2011-06-27 | 2013-01-03 | 株式会社日立製作所 | 細胞培養装置および細胞培養方法 |
WO2013146694A1 (ja) * | 2012-03-28 | 2013-10-03 | コニカミノルタ株式会社 | 生体物質の検出方法 |
WO2013146843A1 (ja) * | 2012-03-30 | 2013-10-03 | コニカミノルタ株式会社 | 医用画像処理装置及びプログラム |
WO2015002082A1 (ja) * | 2013-07-03 | 2015-01-08 | コニカミノルタ株式会社 | 画像処理装置、病理診断支援システム、画像処理プログラム及び病理診断支援方法 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3258264A4 * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2019078230A1 (ja) | 2017-10-19 | 2019-04-25 | コニカミノルタ株式会社 | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム |
JPWO2019078230A1 (ja) * | 2017-10-19 | 2020-12-17 | コニカミノルタ株式会社 | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム |
JP7184046B2 (ja) | 2017-10-19 | 2022-12-06 | コニカミノルタ株式会社 | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム |
US11600020B2 (en) | 2017-10-19 | 2023-03-07 | Konica Minolta, Inc. | Biological substance quantification method, image processing device, pathological diagnosis support system, and recording medium storing computer readable program |
WO2021005904A1 (ja) * | 2019-07-09 | 2021-01-14 | ソニー株式会社 | 情報処理装置およびプログラム |
JP7452544B2 (ja) | 2019-07-09 | 2024-03-19 | ソニーグループ株式会社 | 情報処理装置およびプログラム |
WO2021157397A1 (ja) * | 2020-02-06 | 2021-08-12 | ソニーグループ株式会社 | 情報処理装置及び情報処理システム |
Also Published As
Publication number | Publication date |
---|---|
US10309900B1 (en) | 2019-06-04 |
EP3258264A1 (en) | 2017-12-20 |
US20190154582A1 (en) | 2019-05-23 |
EP3258264A4 (en) | 2018-01-10 |
JPWO2016129061A1 (ja) | 2017-11-24 |
EP3258264B1 (en) | 2020-12-02 |
JP6520961B2 (ja) | 2019-05-29 |
US20180024059A1 (en) | 2018-01-25 |
US10234391B2 (en) | 2019-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5768945B1 (ja) | 生体物質定量方法、画像処理装置、病理診断支援システム及びプログラム | |
JP6504160B2 (ja) | 生体物質定量方法、画像処理装置、病理診断支援システム及び画像処理プログラム | |
US10309900B1 (en) | Biological substance quantitation method, pathological diagnosis support system and recording medium storing computer readable program | |
JP5892238B2 (ja) | 医用画像処理装置及びプログラム | |
JP6717751B2 (ja) | 画像処理方法、画像生成方法、画像処理装置及びプログラム | |
WO2015093518A1 (ja) | 画像処理装置、病理診断支援システム、画像処理プログラム及び画像処理方法 | |
JP5768948B1 (ja) | 画像処理装置および画像処理プログラム | |
JP6597316B2 (ja) | 画像処理装置及びプログラム | |
WO2017126420A1 (ja) | 画像処理装置及びプログラム | |
JP6493398B2 (ja) | 診断支援情報生成方法、画像処理装置、診断支援情報生成システム及び画像処理プログラム | |
JP5835536B1 (ja) | 組織評価方法、画像処理装置、病理診断支援システム及びプログラム | |
JP6372370B2 (ja) | 生体物質定量方法、画像処理装置、及びプログラム | |
WO2018143406A1 (ja) | 画像処理装置及びプログラム | |
JP6337629B2 (ja) | 診断支援情報生成方法、画像処理装置、診断支援情報生成システム及び画像処理プログラム | |
JP6702339B2 (ja) | 画像処理装置及びプログラム | |
JP2016114447A (ja) | 画像処理装置、画像処理システム、画像処理プログラム及び画像処理方法 | |
JP6405985B2 (ja) | 画像処理装置、画像処理システム、画像処理プログラム及び画像処理方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15881936 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016574558 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15549006 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2015881936 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |